Menu
Back to Archived Journals » Research and Reports in Nuclear Medicine » Volume 3
PET imaging using radiolabelled antibodies: future direction in tumor diagnosis and correlate applications
Received 29 April 2013
Accepted for publication 27 June 2013
Published 31 July 2013 Volume 2013:3 Pages 9—17
DOI https://doi.org/10.2147/RRNM.S35186
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Marco Salsano,1 Giorgio Treglia2
1Department of Radiology, Catholic University of Rome, Rome, Italy; 2Department of Nuclear Medicine, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Abstract: Immuno-positron emission tomography (PET) is a new imaging tool that finds application in diagnostic as well as in prognostic and therapeutic oncology. Monoclonal antibodies (mAbs) present the unique ability to selectively bind specific antigens produced by tumors, establishing the presence, location, and number of neoplastic foci. They are produced in unlimited quantities with absolute specificity using the hybridoma method. Treatment with mAbs can have different forms: they can be administered alone or can be combined with a radioactive molecule, which then delivers the radiation directly to the tumor cells. In immuno-PET, mAbs are labeled with various radionuclides and used in cancer patients who produce tumor-associated antigens. In this review we will discuss immuno-PET applications in tumor diseases, focusing on the technique, mAbs, positron emitter selection, and on its future applications.
Keywords: Immuno-PET, monoclonal antibodies, radionuclides, radiolabeling
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.